Leerink Partnrs Decreases Earnings Estimates for BeiGene

BeiGene, Ltd. (NASDAQ:BGNE) – Research analysts at Leerink Partnrs reduced their FY2025 EPS estimates for BeiGene in a report issued on Tuesday, November 12th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn $0.73 per share for the year, down from their prior estimate of $0.79. The consensus estimate for BeiGene’s current full-year earnings is ($5.00) per share. Leerink Partnrs also issued estimates for BeiGene’s FY2026 earnings at $8.11 EPS and FY2027 earnings at $13.54 EPS.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.26 million. BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.15%. BeiGene’s revenue for the quarter was up 28.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.01 EPS.

Several other equities research analysts have also recently weighed in on BGNE. JMP Securities initiated coverage on BeiGene in a research note on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 price target for the company. StockNews.com raised shares of BeiGene from a “hold” rating to a “buy” rating in a research note on Wednesday. TD Cowen boosted their target price on shares of BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a report on Wednesday. Citigroup lifted their price objective on BeiGene from $269.00 to $288.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. Finally, JPMorgan Chase & Co. boosted their price objective on BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research note on Tuesday, October 22nd. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $247.07.

BeiGene Stock Performance

Shares of BeiGene stock opened at $195.45 on Thursday. The stock has a market cap of $19.04 billion, a price-to-earnings ratio of -23.72 and a beta of 0.63. The company has a quick ratio of 1.75, a current ratio of 1.98 and a debt-to-equity ratio of 0.06. BeiGene has a twelve month low of $126.97 and a twelve month high of $248.16. The company’s fifty day moving average is $212.91 and its 200 day moving average is $181.72.

Hedge Funds Weigh In On BeiGene

Large investors have recently modified their holdings of the company. Capital International Investors raised its holdings in shares of BeiGene by 11.5% in the 1st quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock valued at $1,104,806,000 after acquiring an additional 727,556 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in BeiGene during the second quarter valued at approximately $54,412,000. M&G Plc bought a new stake in BeiGene during the first quarter worth about $29,649,000. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of BeiGene by 160.0% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 225,854 shares of the company’s stock valued at $50,706,000 after purchasing an additional 138,978 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of BeiGene by 6.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company’s stock valued at $316,862,000 after buying an additional 117,905 shares in the last quarter. 48.55% of the stock is currently owned by institutional investors.

Insider Activity at BeiGene

In other BeiGene news, SVP Chan Henry Lee sold 1,202 shares of the business’s stock in a transaction on Monday, September 30th. The stock was sold at an average price of $237.10, for a total value of $284,994.20. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, SVP Chan Henry Lee sold 1,202 shares of the stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $237.10, for a total transaction of $284,994.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO John Oyler sold 6,175 shares of the stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $232.22, for a total transaction of $1,433,958.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 23,070 shares of company stock valued at $4,901,050. 7.43% of the stock is owned by insiders.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.